InVitria Sponsors 2010 Biomanufacturing SummitInVitria and biopharmaceutical industry leaders at Biomanufacturing Summit in La Jolla, California January 26th and 27th, 2010. Fort Collins, CO January 26, 2010 - As one of the leading innovators in biomanufacturing technology, InVitria's products enable its customers to optimize their biomanufacturing process from the cell bank through downstream purification.
Biomanufacturing Summit brings thought leaders together to address the major issues facing the biopharmaceutical industry today, including product quality, consistency and cost effectiveness. InVitria's line of defined and performance maximizing cell culture products are designed to solve these challenges.
"InVitria is pleased to once again serve as a sponsor for Biomanufacturing Summit," said Scott Deeter, InVitria President and CEO. "This event is a great opportunity to collaborate with existing biopharma customers and identify new opportunities to deliver integrated solutions that optimize mammalian cell culture and viral vaccine manufacturing."
One of InVitria's newly developed products for biomanufacturers is Zap-CHO, a robust CHO cell line supplement designed to improve CHO growth and productivity and simultaneously improve downstream purification efficiency. To view an online video featuring the benefits of Zap-CHO, click here.
Cellastim and Lacromin, two of InVitria's other performance enhancing cell culture supplements, will be highlighted in a presentation by Dr. Matt Croughan, Director of the Amgen Bioprocessing Center at the Keck Graduate Institute. To receive a copy of Dr. Croughan's presentation, please contact InVitria. To request more information about InVitria's products, e-mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call 1-800-916-8311
|
-
Blog: The Cell Culture Dish
Strategies for Improving Viral Yield in Vaccine Manufacturing
A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More
-
Latest News
InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference
March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more
